Novel platform technology for modular mucosal vaccine that protects against streptococcus

Area of Science:

• Immunology
• Vaccinology
• Microbiology

Background:

• The upper respiratory tract (URT) is a primary entry point for numerous human pathogens.
• Group A Streptococcus (GAS) infections cause significant morbidity and mortality, including rheumatic fever and heart disease.

Purpose of the Study:

• To develop an innovative vaccine strategy to induce potent mucosal antibodies against GAS.
• To utilize a novel biocompatible liposomal platform for vaccine delivery and immune response activation.

Main Methods:

• Encapsulation of diphtheria toxoid (DT) within liposomes for T-cell stimulation.
• Surface display of lipidated peptide antigens on liposomes for B-cell activation.
• Development of modular constructs to activate B-cells with complementary specificities.

Main Results:

• The liposomal platform successfully induced significant mucosal antibody responses against GAS peptide antigens.
• The vaccine strategy elicited both humoral (IgA) and cellular immune responses.
• Profound protection against URT streptococcal infection was achieved in the study model.

Conclusions:

• The described liposomal vaccine platform is effective in generating protective mucosal immunity against GAS.
• This platform technology is applicable for developing vaccines against various mucosal pathogens.
• The modular design allows for simultaneous activation of B-cells targeting distinct virulence factors.